By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Immunomedics, Inc. 

300 American Road

Morris Plains  New Jersey  07950-2450  U.S.A.
Phone: 201-605-8200 Fax: 973-605-8282



Company News
Immunomedics, Inc. (IMMU) Presents Updated Results With Sacituzumab Govitecan in Lung Cancer 2/20/2015 7:26:10 AM
Immunomedics, Inc. (IMMU) Announces Completion Of Offering Of $85 Million Of 4.75% Convertible Senior Notes Due 2020 2/12/2015 7:29:14 AM
Immunomedics, Inc. (IMMU) Announces Pricing Of Offering of $85 Million Of 4.75% Convertible Senior Notes Due 2020 2/6/2015 7:38:09 AM
Immunomedics, Inc. (IMMU) Announces Proposed Offering of $85 Million of Convertible Senior Notes Due 2020 2/5/2015 7:56:32 AM
Immunomedics, Inc. (IMMU) Announces Conference Call And Webcast For Second Quarter Fiscal 2015 Financial Results 2/4/2015 10:10:18 AM
Immunomedics, Inc. (IMMU) Announces Dismissal Of Putative Class Action Lawsuit 1/29/2015 7:59:44 AM
Immunomedics, Inc. (IMMU) Reports Phase 1/2 Results With Sacituzumab Govitecan (IMMU-132) In Patients With Metastatic Gastrointestinal Cancers 1/20/2015 7:12:48 AM
Immunomedics, Inc. (IMMU) Appoints Dr. Francois Wilhelm Chief Medical Officer 1/6/2015 7:32:08 AM
Immunomedics, Inc. (IMMU) Awarded Fast Track Designation By FDA For Sacituzumab Govitecan (IMMU-132) For Triple-Negative Breast Cancer Therapy 1/5/2015 7:07:39 AM
Immunomedics, Inc. (IMMU) Reports Preliminary Results From Pretargeted Imaging Study In Patients With Metastatic Breast Cancer 12/15/2014 7:32:09 AM